- Home
- CRDF vs FDMT Comparison
CRDF vs FDMT Comparison
Compare CRDF & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDF | FDMT |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1M | 391.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRDF | FDMT |
|---|---|---|
| Price | $2.52 | $8.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.63 | ★ $30.33 |
| AVG Volume (30 Days) | ★ 917.3K | 899.3K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $501,000.00 | $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | N/A | $162.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $1.90 | $2.24 |
| 52 Week High | $5.64 | $12.34 |
Technical Indicators
Market Signals| Indicator | CRDF | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 36.25 |
| Support Level | $2.32 | $10.56 |
| Resistance Level | $2.59 | $11.81 |
| Average True Range (ATR) | 0.14 | 0.89 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 87.61 | 3.28 |
Price Performance
Historical ComparisonAbout CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.